Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19

Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactives, for activity against a South Korean Middle East respiratory syndrome coronavirus (MERS-CoV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Meehyun, Chang, So Young, Byun, Soo Young, Ianevski, Aleksandr, Choi, Inhee, Pham Hung d’Alexandry d’Orengiani, Anne-Laure, Ravlo, Erlend, Wang, Wei, Bjørås, Magnar, Kainov, Denis E., Shum, David, Min, Ji-Young, Windisch, Marc P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069929/
https://www.ncbi.nlm.nih.gov/pubmed/33918958
http://dx.doi.org/10.3390/v13040651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069929/
https://www.ncbi.nlm.nih.gov/pubmed/33918958
http://dx.doi.org/10.3390/v13040651

Ejemplares similares